风湿

RA患者持续低疾病活动10年研究结果相似

作者:韩青 空军军医大学附属西京医院临床免疫科 来源:西京风湿免疫 日期:2017-11-07
导读

         无论是否有诱导缓解治疗,持续低疾病活动的患者经长期观察有类似的结果,只有在MTX单一疗法后,有较高比例的患者获得无药物缓解。

关键字:  RA 

        摘 要

        目的

        比较持续低疾病活动的RA患者10年的研究结果,初始英夫利昔单抗或激素和SSZ联合或无MTX治疗。

        方法

        从Behandel Strategieen (最好的治疗策略)的研究中,对近10年的RA患者随访结果进行了分析,治疗目标严格控制在DAS ⩽ 2.4。被选中的RA患者从6个月到10年都有较低的疾病活动度,因此没有加强治疗。患者被分成接受MTX单一疗法的患者和接受最初联合治疗的患者。用(广义的)线性混合模型分析比较了组间差异,对DAS、HAQ、ESR、视觉模拟量表、患者健康评估、患者(无药物)缓解率的百分比以及夏普/范德赫德评分的患者百分比。

        结果

        在10年的观察中,与68/261(26%)联合治疗的患者相比(所有人都逐渐减少到单一疗法或无药物治疗),MTX单一疗法(一些逐渐减少到无药物治疗)的患者中,有28/247(11%)的患者持续DAS<2.4。随着时间的推移,持续反应者之间无组间差异,MTX单一药物治疗后无药物缓解的患者比例较高。DAS、ESR和视觉模拟量表、患者总体健康评估之间有相互影响,但结果在临床上可忽略不计。

        结论

        最初使用强的松或英夫利昔单抗联合治疗的患者比单用MTX单药治疗的患者达到低疾病活动人数多,但未发现额外的受益。无论是否有诱导缓解治疗,持续低疾病活动的患者经长期观察有类似的结果,只有在MTX单一疗法后,有较高比例的患者获得无药物缓解。

        原 文

        Abstract

        OBJECTIVES:

        To compare 10-year disease outcomes of RA patients who havecontinuous low disease activity and are on MTX with or without initialcombination therapy with infliximab or prednisone and SSZ.

        METHODS:

        Recent-onset RA patients from the Behandel Strategieen (BeSt)(Dutch acronym for Treatment Strategies) study with 10 years of follow-up wereanalysed. Treatment was tightly controlled, targeted at DAS ⩽ 2.4. The selected patientshad low disease activity from 6 months until 10 years and therefore did notintensify treatment. Patients were grouped into those receiving MTX monotherapyand those receiving initial combination therapy. Between-group differences overtime were compared, using (generalized) linear mixed model analyses, for theoutcomes DAS, HAQ, ESR, visual analogue scale patient global health, percentageof patients in (drug-free) remission and percentage of patients with Sharp/vander Heijde score progression ⩾5.

        RESULTS:

        At 10 years, 28/247 (11%) patients on MTX monotherapy (sometapered to drug free) had continued DAS ⩽ 2.4 compared with 68/261(26%) patients on combination therapy (all tapered to monotherapy or drugfree). No between-group differences in continuous responders were found over time,except for a higher percentage of patients in drug-free remission after MTXmonotherapy. Significant group-time interactions were found for DAS, ESR andvisual analogue scale patient global health, but the results seem clinicallynegligible.

        CONCLUSION:

        More patients achieved continuous low disease activity on initialprednisone or infliximab combination therapy than on initial MTX monotherapy,but there appeared to be no additional benefits. Regardless of inductiontherapy, patients with continuous low disease activity have similar long-termoutcomes, with only a higher proportion of patients in drug-free remissionafter MTX monotherapy.

        引自:Bergstra SA, Landewé RBM, Huizinga TWJ, AllaartCF.Rheumatoidarthritispatients with continued low disease activity have similar outcomes over 10years, regardless of initial therapy.Rheumatology(Oxford).2017Oct1; 56(10): 1721-1728. doi:10.1093/rheumatology/kex236.

        翻译者:韩青 空军军医大学附属西京医院临床免疫科

        转自:西京风湿免疫

分享:

评论

我要跟帖
发表
回复 小鸭梨
发表

copyright©医学论坛网 版权所有,未经许可不得复制、转载或镜像 京ICP证120392号 京公网安备11010502031486号

京卫网审[2013]第0193号

互联网药品信息服务资格证书:(京)-经营性-2012-0005

//站内统计 //百度统计 //站长统计
*我要反馈: 姓    名: 邮    箱: